title: Preclinical Efficacy of Clumping Factor A in Prevention of Staphylococcus aureus Infection.
abstract: Treatment of Staphylococcus aureus infections has become increasingly difficult because of the emergence of multidrug-resistant isolates. Development of a vaccine to prevent staphylococcal infections remains a priority. To determine whether clumping factor A (ClfA) is a good target protein for inclusion in a multivalent vaccine, we evaluated its efficacy in a variety of relevant staphylococcal infection models, challenging with different S. aureus strains. ClfA adsorbed to Alhydrogel and mixed with Sigma Adjuvant System was more immunogenic and stimulated a more robust Th17 response than ClfA administered with alum alone. ClfA immunization induced the production of functional antibodies in rabbits and mice that blocked S. aureus binding to fibrinogen and were opsonic for S. aureus strains that produced little or no capsular polysaccharide. Mice immunized with ClfA showed a modest reduction in the bacterial burden recovered from subcutaneous abscesses provoked by S. aureus USA300 strain LAC. In addition, the ClfA vaccine reduced lethality in a sepsis model following challenge with strain Newman, but not ST80. Vaccination with ClfA did not protect against surgical wound infection, renal abscess formation, or bacteremia. Passive immunization with antibodies to ClfA did not protect against staphylococcal bacteremia in mice or catheter-induced endocarditis in rats. Some enhancement of bacteremia was observed by ClfA immunization or passive administration of ClfA antibodies when mice were challenged by the intraperitoneal route. Although rodent models of staphylococcal infection have their limitations, our data do not support the inclusion of ClfA in an S. aureus multivalent vaccine.
  
  
  OBJECTIVE
  Antibiotics are often ineffective in eradicating Staphylococcus aureus infections, and thus, a preventative vaccine is sorely needed. Two single-component vaccines and two immunoglobulin preparations failed to meet their designated endpoints in phase III clinical trials. Importantly, recipients of an S. aureus surface protein (iron surface determinant B) vaccine who developed a staphylococcal infection experienced a higher rate of multiorgan failure and mortality than placebo controls, raising safety concerns. Multicomponent S. aureus vaccines have now been generated, and several include surface protein clumping factor A (ClfA). We immunized mice with ClfA and generated a robust T cell response and serum antibodies that were functional in vitro. Nonetheless, ClfA was not protective in a number of relevant animal models of S. aureus infection, and high levels of ClfA antibodies enhanced bacteremia when mice were challenged with community-acquired methicillin-resistant S. aureus strains. Evidence supporting ClfA as a vaccine component is lacking.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
authors.forename: Xue
authors.initials: X
authors.lastname: Li
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Xiaogang
authors.initials: X
authors.lastname: Wang
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Christopher D
authors.initials: CD
authors.lastname: Thompson
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Saeyoung
authors.initials: S
authors.lastname: Park
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
authors.forename: Wan Beom
authors.initials: WB
authors.lastname: Park
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA jclee@bwh.harvard.edu.
authors.forename: Jean C
authors.initials: JC
authors.lastname: Lee
mesh_terms: D000038:Abscess / Q000382:microbiology; D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood / Q000627:therapeutic use; D000942:Antigens, Bacterial / Q000276:immunology*; D058491:Bacterial Load; D003030:Coagulase / Q000276:immunology*; D004353:Drug Evaluation, Preclinical; D051379:Mice; D008810:Mice, Inbred C57BL; D010919:Placebos / Q000008:administration & dosage; D017207:Rats, Sprague-Dawley; D018805:Sepsis / Q000401:mortality; D013203:Staphylococcal Infections / Q000517:prevention & control*; D013209:Staphylococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016019:Survival Analysis; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; C515944:ClfA protein, Staphylococcus aureus; D003030:Coagulase; D010919:Placebos; D013209:Staphylococcal Vaccines; D022223:Vaccines, Subunit
references.citation: J Infect Dis. 2006 Dec 15;194(12):1761-70
references.pmid: 17109350
references.citation: J Pediatr. 2007 Sep;151(3):260-5, 265.e1
references.pmid: 17719934
references.citation: PLoS One. 2008;3(5):e2206
references.pmid: 18493318
references.citation: J Infect Dis. 2008 Jul 1;198(1):125-33
references.pmid: 18544012
references.citation: Vaccine. 2009 May 26;27(25-26):3276-80
references.pmid: 19200819
references.citation: Nat Rev Microbiol. 2009 Sep;7(9):629-41
references.pmid: 19680247
references.citation: PLoS Pathog. 2009 Dec;5(12):e1000703
references.pmid: 20041174
references.citation: Infect Immun. 2010 Apr;78(4):1717-27
references.pmid: 20100856
references.citation: J Clin Invest. 2010 May;120(5):1762-73
references.pmid: 20364087
references.citation: Expert Opin Biol Ther. 2010 Jul;10(7):1049-59
references.pmid: 20528609
references.citation: J Exp Med. 2010 Aug 30;207(9):1863-70
references.pmid: 20713595
references.citation: Infect Immun. 2010 Oct;78(10):4234-42
references.pmid: 20679443
references.citation: Annu Rev Pathol. 2011;6:19-48
references.pmid: 20887193
references.citation: Hum Vaccin. 2011 Jan-Feb;7 Suppl:51-9
references.pmid: 21245656
references.citation: PLoS Pathog. 2011 Oct;7(10):e1002307
references.pmid: 22028651
references.citation: J Bacteriol. 2012 Mar;194(6):1625-6
references.pmid: 22374956
references.citation: Clin Vaccine Immunol. 2012 Oct;19(10):1641-50
references.pmid: 22896688
references.citation: Blood. 2013 Mar 7;121(10):1783-94
references.pmid: 23299312
references.citation: Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10408-13
references.pmid: 16801559
references.citation: Antimicrob Agents Chemother. 2006 Aug;50(8):2751-5
references.pmid: 16870768
references.citation: Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16942-7
references.pmid: 17075065
references.citation: JAMA. 2013 Apr 3;309(13):1368-78
references.pmid: 23549582
references.citation: Clin Vaccine Immunol. 2013 Aug;20(8):1338-40
references.pmid: 23803901
references.citation: Methods Mol Biol. 2014;1085:85-95
references.pmid: 24085690
references.citation: PLoS Pathog. 2013;9(10):e1003653
references.pmid: 24130480
references.citation: JAMA Intern Med. 2013 Nov 25;173(21):1970-8
references.pmid: 24043270
references.citation: Nat Rev Microbiol. 2014 Jan;12(1):49-62
references.pmid: 24336184
references.citation: Infect Immun. 2014 Jan;82(1):83-91
references.pmid: 24126523
references.citation: J Infect Dis. 2014 May 15;209(10):1551-61
references.pmid: 24308931
references.citation: Microbiology. 2014 Apr;160(Pt 4):659-70
references.pmid: 24464799
references.citation: J Biol Chem. 2014 Feb 7;289(6):3478-86
references.pmid: 24344128
references.citation: Hum Vaccin Immunother. 2013 Mar;9(3):480-7
references.pmid: 23249887
references.citation: APMIS. 2014 Dec;122(12):1240-50
references.pmid: 25051890
references.citation: Vaccine. 2015 Apr 8;33(15):1846-54
references.pmid: 25707693
references.citation: Hum Vaccin Immunother. 2015;11(3):620-31
references.pmid: 25715157
references.citation: J Med Microbiol. 2015 Apr;64(Pt 4):335-43
references.pmid: 25878259
references.citation: Vaccine. 2015 Oct 5;33(41):5452-7
references.pmid: 26319743
references.citation: Infect Immun. 2001 Feb;69(2):917-23
references.pmid: 11159986
references.citation: Infect Immun. 2001 May;69(5):3120-7
references.pmid: 11292731
references.citation: J Infect Dis. 2001 Dec 15;184(12):1572-80
references.pmid: 11740733
references.citation: N Engl J Med. 2002 Feb 14;346(7):491-6
references.pmid: 11844850
references.citation: EMBO J. 2002 Dec 16;21(24):6660-72
references.pmid: 12485987
references.citation: J Clin Invest. 2003 May;111(9):1265-73
references.pmid: 12727914
references.citation: Antimicrob Agents Chemother. 2003 Nov;47(11):3400-6
references.pmid: 14576094
references.citation: Infect Immun. 1982 Jul;37(1):127-31
references.pmid: 7049946
references.citation: J Infect Dis. 1987 Nov;156(5):741-50
references.pmid: 2821124
references.citation: Mol Microbiol. 1994 Jan;11(2):237-48
references.pmid: 8170386
references.citation: Infect Immun. 1995 Dec;63(12):4738-43
references.pmid: 7591130
references.citation: Eur J Biochem. 1997 Jul 1;247(1):416-24
references.pmid: 9249055
references.citation: Infect Immun. 1997 Oct;65(10):4146-51
references.pmid: 9317020
references.citation: N Engl J Med. 1998 Aug 20;339(8):520-32
references.pmid: 9709046
references.citation: Science. 1998 Aug 21;281(5380):1197-200
references.pmid: 9712585
references.citation: Infect Immun. 1998 Nov;66(11):5183-9
references.pmid: 9784520
references.citation: Science. 1999 Jul 30;285(5428):760-3
references.pmid: 10427003
references.citation: J Gen Microbiol. 1952 Feb;6(1-2):95-107
references.pmid: 14927856
references.citation: Vaccine. 2004 Dec 6;22 Suppl 1:S39-43
references.pmid: 15576200
references.citation: Infect Immun. 2005 Jun;73(6):3502-11
references.pmid: 15908379
references.citation: Eur J Clin Microbiol Infect Dis. 2005 Jun;24(6):419-22
references.pmid: 15937659